Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Yimer, Getnet ^a,b   Ueda, Nobuhisa ^a   Habtewold, Abiy ^a,b   Amogne, Wondwossen ^a,b   Suda, Akira ^a   Riedel, Klaus Dieter ^c   Burhenne, Jürgen ^c   Aderaye, Getachew ^b   Lindquist, Lars ^a   Makonnen, Eyasu ^b   Aklillu, Eleni ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYEFAVIRENZ; ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CREATININE; DRUG METABOLITE; EFAVIRENZ; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; HEMOGLOBIN; LAMIVUDINE; RIFAMPICIN; STAVUDINE; TENOFOVIR; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UREA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; TUMOR MARKER;

ABCB1 GENE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYP2B6 GENE; CYP3A5 GENE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FATALITY; DRUG METABOLISM; DRUG MONITORING; DRUG TRANSPORT; ETHIOPIA; FEMALE; GENE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NAT2 GENE; PATIENT IDENTIFICATION; PHARMACOGENETICS; PREDICTION; PROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; SLCO1B1 GENE; SURVIVAL; TOXIC HEPATITIS; TUBERCULOSIS; UGT2B7 GENE; UREA BLOOD LEVEL; ADOLESCENT; COMORBIDITY; DRUG EFFECT; LIVER; METABOLISM; MIDDLE AGED; TIME;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; BENZOXAZINES; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; LIVER; MALE; MIDDLE AGED; PHARMACOGENETICS; PROSPECTIVE STUDIES; RIFAMPIN; TIME FACTORS; TUBERCULOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 82755165151     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027810     Document Type: Article

References (60)

1. Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, et al. (2009) Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis 15: 258-264.
2. McIlleron H, Meintjes G, Burman WJ, Maartens G, (2007) Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196 (Suppl 1): S63-75.
3. Walker UA, (2007) Antiretroviral therapy-induced liver alterations. Curr Opin HIV AIDS 2: 293-298.
4. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD, (2003) Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 34: 379-386.
5. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, et al. (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23: 192-202.
6. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, et al. (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174: 935-952.
7. Wares DF, Singh S, Acharya AK, Dangi R, (2003) Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. Int J Tuberc Lung Dis 7: 327-335.
8. Kontorinis N, Dieterich DT, (2003) Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 23: 173-182.
9. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V, (1998) Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 12: 1256.
10. Coffie PA, Tonwe-Gold B, Tanon AK, Amani-Bosse C, Bedikou G, et al. (2010) Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Cote d'Ivoire. BMC Infect Dis 10: 188.
11. Nunez M, (2010) Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 52: 1143-1155.
12. Kwara A, Flanigan TP, Carter EJ, (2005) Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis 9: 248-257.
13. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. Aids 16: 75-83.
14. UNAIDS (2008) 2008 Report on the Global AIDS Epidemic Geneva UNAIDS; August 2008.
15. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, et al. (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306: 287-300.
16. Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, et al. (1999) Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 27: 1319-1333.
17. di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, et al. (2009) In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 19: 300-309.
18. Bae SK, Jeong YJ, Lee C, Liu KH, (2011) Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica 41: 437-444.
19. Mukonzo JK, Roshammar D, Waako P, Andersson M, Fukasawa T, et al. (2009) A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 68: 690-699.
20. Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, et al. (2010) Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 11: 1223-1234.
21. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, et al. (2005) Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 192: 1931-1942.
22. Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, et al. (2007) The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. European Journal of Clinical Pharmacology 63: 633-639.
23. Daly AK, (2010) Drug-induced liver injury: past, present and future. Pharmacogenomics 11: 607-611.
24. Russmann S, Jetter A, Kullak-Ublick GA, (2010) Pharmacogenetics of drug-induced liver injury. Hepatology 52: 748-761.
25. Vidal F, Gutierrez F, Gutierrez M, Olona M, Sanchez V, et al. (2010) Pharmacogenetics of adverse effects due to antiretroviral drugs. AIDS Rev 12: 15-30.
26. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K, (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36: 164-172.
27. Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, et al. (2004) Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos 32: 348-358.
28. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, et al. (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320: 72-80.
29. Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel KD, et al. (2011) Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. The Journal of Antimicrobial Chemotherapy 66: 2350-2361.
30. Niemi M, Kivisto KT, Diczfalusy U, Bodin K, Bertilsson L, et al. (2006) Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenetics and Genomics 16: 565-568.
31. Desta Z, Soukhova NV, Flockhart DA, (2001) Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 45: 382-392.
32. Haas DW, Koletar SL, Laughlin L, Kendall MA, Suckow C, et al. (2009) Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr 50: 290-293.
33. Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, et al. (2011) High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J Aug 23. doi: 10.1038/tpj.2011.34.
34. Wen X, Wang JS, Neuvonen PJ, Backman JT, (2002) Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 57: 799-804.
35. Djordjevic N, Carrillo JA, Ueda N, Gervasini G, Fukasawa T, et al. (2011) N-acetyltransferase-2 (NAT2) Gene Polymorphisms and Enzyme Activity in Serbs: Unprecedented High Prevalence of Rapid Acetylators in a White Population. J Clin Pharmacol 51: 994-1003.
36. Anitha A, Banerjee M, (2003) Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India. International Journal of Molecular Medicine 11: 125-131.
37. Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, et al. (2010) Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 88: 676-684.
38. Benichou C, (1990) Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11: 272-276.
39. Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, et al. (2008) Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. PLoS ONE 3: e1809.
40. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, et al. (2007) Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 21: 1301-1308.
41. Shipton LK, Wester CW, Stock S, Ndwapi N, Gaolathe T, et al. (2009) Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis 13: 360-366.
42. Cohen K, Meintjes G, (2010) Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS 5: 61-69.
43. Stohr W, Back D, Dunn D, Sabin C, Winston A, et al. (2008) Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 13: 675-685.
44. Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, et al. (2009) Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G&T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 14: 687-695.
45. Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, et al. (2009) Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 50: 439-443.
46. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, et al. (2009) CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 53: 863-868.
47. Saitoh A, Fletcher CV, Brundage R, Alvero C, Fenton T, et al. (2007) Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr 45: 280-285.
48. Apostolova N, Gomez-Sucerquia LJ, Moran A, Alvarez A, Blas-Garcia A, et al. (2010) Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol 160: 2069-2084.
49. Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A, Esplugues JV, (2011) Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. Hepatology 54: 1009-1019.
50. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, et al. (1976) Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84: 181-192.
51. Yamamoto T, Suou T, Hirayama C, (1986) Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 6: 295-298.
52. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, et al. (1975) Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 18: 70-79.
53. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, et al. (2000) Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4: 256-261.
54. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, et al. (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35: 883-889.
55. Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, et al. (2007) NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 13: 6003-6008.
56. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, et al. (2008) Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 64: 673-681.
57. Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, et al. (2009) Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 10: 1433-1445.
58. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, et al. (2006) CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 62: 423-429.
59. Diaz-Molina R, Cornejo-Bravo JM, Ramos-Ibarra MA, Estrada-Guzman JD, Morales-Arango O, et al. (2008) Genotype and phenotype of NAT2 and the occurrence of adverse drug reactions in Mexican individuals to an isoniazid-based prophylactic chemotherapy for tuberculosis. Mol Med Report 1: 875-879.
60. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528.